US$2.07+1.0%11月13日 收盘
数据截至2026年9月30日，来自2026年11月9日提交的10-Q
Just reported
From Foghorn Therapeutics Inc.'s results release of 2026年11月9日; its quarterly report has since been filed.
Actual
US$83.5M
Guided
—
No guide given
Actual
US$0.80
Guided
—
No guide given
Actual
US$56.6M
Guided
—
No guide given
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$83.5M | US$8.2M | +924.69% |
| 利润 | US$58.2M | -US$15.8M | +466.90% |
| 每股收益 | US$0.80 | -US$0.25 | +420.00% |
| 自由现金流 | -US$18.3M | -US$18.9M | +3.23% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
Foghorn Therapeutics Inc. reported on 2026年11月9日. We are fetching the call transcript; its summary follows once the transcript is in.
“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Therapeutics Foghorn® Therapeutics is a biotechnology company developing novel medicines against challenging biological targets through multiple modalities and approaches, including oral small molecules, targeted protein degradation, and induced proximity. The Company is advancing programs in oncology as well as immunology and inflammation. Foghorn brings together deep biological understanding and small-molecule drug discovery expertise to pursue challenging targets with selectivity. Visit our website at www.foghorntx.com
公司自己的描述，取自公告末尾。
引述和公司简介来自 Foghorn Therapeutics Inc. 于 2026年11月9日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.